We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$740M
AUM Growth
-$43.3M
Cap. Flow
-$86.3M
Cap. Flow %
-11.66%
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.8M
2
GILD icon
Gilead Sciences
GILD
+$9.89M
3
COR icon
Cencora
COR
+$7.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.72M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$6.41M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$20.2M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.8M
3
ABMD
Abiomed Inc
ABMD
+$10M
4
AET
Aetna Inc
AET
+$9.86M
5
CVS icon
CVS Health
CVS
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 90.07%
2 Financials 0.19%
3 Technology 0.17%
4 Energy 0.14%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
26
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$10.3M 1.39%
211,153
-86,247
-29% -$4.36M
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$4.9B
$10.2M 1.38%
+338,882
New +$10.8M
AGN
28
DELISTED
Allergan plc
AGN
$9.66M 1.31%
59,052
-40,948
-41% -$7.35M
NVCR icon
29
NovoCure
NVCR
$1.83B
$9.45M 1.28%
467,569
-198,959
-30% -$3.83M
CI icon
30
Cigna
CI
$72.7B
$9.22M 1.25%
45,400
-9,600
-17% -$1.91M
NBIX icon
31
Neurocrine Biosciences
NBIX
$16.2B
$9.15M 1.24%
117,969
+2,969
+3% +$203K
BSX icon
32
Boston Scientific
BSX
$71.4B
$8.63M 1.17%
347,968
+67,500
+24% +$1.86M
EW icon
33
Edwards Lifesciences
EW
$51.5B
$8.27M 1.12%
220,092
-19,908
-8% -$731K
KYNB
34
Kyntra Bio
KYNB
$28.3M
$8.04M 1.09%
6,782
+962
+17% +$1.21M
BMY icon
35
Bristol-Myers Squibb
BMY
$131B
$7.95M 1.07%
129,802
-30,700
-19% -$1.92M
IMMU
36
DELISTED
Immunomedics Inc
IMMU
$7.76M 1.05%
480,330
-19,670
-4% -$232K
LOXO
37
DELISTED
Loxo Oncology, Inc
LOXO
$7.6M 1.03%
90,280
+15,280
+20% +$1.27M
AERI
38
DELISTED
Aerie Pharmaceuticals
AERI
$7.58M 1.02%
126,829
+5,897
+5% +$358K
IOVA icon
39
Iovance Biotherapeutics
IOVA
$2.77B
$7.55M 1.02%
944,185
+233,022
+33% +$1.87M
MYOK
40
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$7.5M 1.01%
178,272
+27,400
+18% +$1.06M
RIGL icon
41
Rigel Pharmaceuticals
RIGL
$733M
$7.5M 1.01%
193,283
-41,717
-18% -$1.59M
ALNY icon
42
Alnylam Pharmaceuticals
ALNY
$28.9B
$7.49M 1.01%
58,967
+16,174
+38% +$2.03M
ELV icon
43
Elevance Health
ELV
$84.9B
$6.97M 0.94%
31,000
-24,000
-44% -$5.11M
ABT icon
44
Abbott
ABT
$187B
$6.96M 0.94%
122,000
-33,000
-21% -$1.83M
XNCR icon
45
Xencor
XNCR
$1.48B
$6.96M 0.94%
317,500
+67,500
+27% +$1.46M
FLXN
46
DELISTED
Flexion Therapeutics, Inc.
FLXN
$6.55M 0.89%
+261,686
New +$6.41M
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.53M 0.88%
182,580
-63,820
-26% -$1.83M
ARRY
48
DELISTED
Array Biopharma Inc
ARRY
$6.44M 0.87%
503,059
-146,941
-23% -$1.67M
UHS icon
49
Universal Health Services
UHS
$10.3B
$5.94M 0.8%
52,433
+2,433
+5% +$260K
MGNX icon
50
MacroGenics
MGNX
$255M
$5.86M 0.79%
308,604
+86,690
+39% +$1.62M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
OC
Oarsman Capital Milwaukee, Wisconsin $806M AUM 19.96% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rhenman & Partners Asset Management held 104 positions worth $740M, down 5.5% from $783M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $86.3M in Q4 2017, closing 9 positions and reducing 49 holdings. Its most notable exit was Aetna Inc, an estimated $9.86M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Acadia Pharmaceuticals worth $10.2M.

  • Rhenman & Partners Asset Management's largest Q4 2017 buy was Acadia Pharmaceuticals: 338,882 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2017, an estimated $9.89M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $20.2M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2017, selling an estimated $9.86M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $740M portfolio in Q4 2017.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 9 in Q4 2017.
  • Rhenman & Partners Asset Management's portfolio value fell 5.5% quarter-over-quarter to $740M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2017, filed 19 Jan 2018.